Skip to main content
. Author manuscript; available in PMC: 2021 Mar 20.
Published in final edited form as: Ann Intern Med. 2020 Mar 24;172(8):523–532. doi: 10.7326/M19-2945

Figure 1.

Figure 1.

Cumulative incidence of anemia (hemoglobin level <130 g/L in men or <120 g/L in women) in the placebo group compared with all canakinumab dose groups combined (top) and with the groups receiving 50, 150, or 300 mg of canakinumab once every 3 months (bottom).

HR = hazard ratio.